BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31624895)

  • 1. Prognostic Impact of Osteopenia in Patients Who Underwent Living Donor Liver Transplantation for Hepatocellular Carcinoma.
    Toshima T; Yoshizumi T; Kosai-Fujimoto Y; Inokuchi S; Yoshiya S; Takeishi K; Itoh S; Harada N; Ikegami T; Soejima Y; Mori M
    World J Surg; 2020 Jan; 44(1):258-267. PubMed ID: 31624895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients.
    Sharma P; Parikh ND; Yu J; Barman P; Derstine BA; Sonnenday CJ; Wang SC; Su GL
    Liver Transpl; 2016 Aug; 22(8):1092-8. PubMed ID: 27064263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of hepatocellular carcinoma in Child-Pugh class B cirrhotic patients: hepatic resection and/or microwave coagulation therapy versus living donor liver transplantation.
    Harada N; Shirabe K; Ikeda Y; Korenaga D; Takenaka K; Maehara Y
    Ann Transplant; 2012 Dec; 17(4):11-20. PubMed ID: 23274319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
    Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
    J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-based Prognostic Score in Patients with Living Donor Liver Transplantation for Hepatocellular Carcinoma.
    Harimoto N; Yoshizumi T; Shimagaki T; Nagatsu A; Motomura T; Harada N; Okabe H; Itoh S; Ikegami T; Uchiyama H; Soejima Y; Maehara Y
    Anticancer Res; 2016 Oct; 36(10):5537-5542. PubMed ID: 27798927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
    Shimada M; Yonemura Y; Ijichi H; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Maehara Y
    Transplant Proc; 2005 Mar; 37(2):1177-9. PubMed ID: 15848661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
    Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
    J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation.
    Kim SH; Lee EC; Na BG; Park SJ
    Eur J Surg Oncol; 2019 Feb; 45(2):180-186. PubMed ID: 30243467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma.
    Shin WY; Suh KS; Lee HW; Kim J; Kim T; Yi NJ; Lee KU
    Liver Transpl; 2010 May; 16(5):678-84. PubMed ID: 20440777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma.
    Yokoi H; Isaji S; Yamagiwa K; Tabata M; Nemoto A; Sakurai H; Usui M; Uemoto S
    J Hepatobiliary Pancreat Surg; 2006; 13(2):123-30. PubMed ID: 16547673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.
    Lee EC; Kim SH; Shim JR; Park SJ
    Liver Transpl; 2018 Jan; 24(1):35-43. PubMed ID: 28885774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.